--- title: "Health In Tech | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 8.772 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286312924.md" datetime: "2026-05-13T20:29:10.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286312924.md) - [en](https://longbridge.com/en/news/286312924.md) - [zh-HK](https://longbridge.com/zh-HK/news/286312924.md) --- # Health In Tech | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 8.772 M Revenue: As of FY2026 Q1, the actual value is USD 8.772 M, beating the estimate of USD 7.464 M. EPS: As of FY2026 Q1, the actual value is USD -0.03. EBIT: As of FY2026 Q1, the actual value is USD -2.226 M. #### Revenue Health In Tech, Inc.’s total revenue increased 9.4% to $8.8 million in the first quarter of 2026, up from $8.0 million in the first quarter of 2025. Revenues from underwriting modeling (ICE) were $1,468,814 in 2026, compared to $2,351,984 in 2025. Revenues from fees (SMR) were $7,302,832 in 2026, compared to $5,663,000 in 2025. #### Operational Metrics Cost of revenues increased to $4,262,247 in the first quarter of 2026 from $2,659,585 in the prior year period. Gross profit was $4,509,399 in 2026, down from $5,355,399 in 2025. Total operating expenses for the first quarter of 2026 were $6,667,554, an increase from $4,874,741 in the first quarter of 2025. Sales and marketing expenses rose to $2,291,601 in 2026 from $1,090,255 in 2025. General and administrative expenses were $3,455,558 in 2026, compared to $3,246,765 in 2025. Research and development expenses increased to $920,395 in 2026 from $537,721 in 2025. Income (loss) before income taxes was - $2,068,350 in 2026, shifting from an income of $684,423 in 2025. Net loss equaled - $1,588,281 in the first quarter of 2026, compared to net income of $498,592 in the first quarter of 2025. Adjusted EBITDA totaled - $1.3 million, compared to $1.2 million in the first quarter of 2025. #### Cash Flow Net cash used in operating activities was - $3,319,247 for the three months ended March 31, 2026, compared to net cash provided by operating activities of $527,353 in the same period of 2025. Net cash used in investing activities was - $362,131 in 2026, compared to - $703,475 in 2025. Net cash provided by financing activities was $6,336,832 in 2026, primarily due to proceeds from the issuance of common stock, compared to net cash used of - $98,089 in 2025. Cash and cash equivalents increased by $2,655,454 in 2026, resulting in a balance of $10,325,208 at the end of the period, compared to $7,575,037 at the end of the prior year period. #### Unique Metrics Platform placed plan value (PPPV) totaled $82.0 million. Distribution partners, including brokers, third-party administrators, and agencies, reached 896, marking a 29.5% increase from 692 as of March 31, 2025. Contracted revenue for the remaining three quarters of 2026 equaled $22.9 million. #### Outlook / Guidance Health In Tech, Inc. reiterated its guidance for 2026 annual revenue, expecting it to range between $45 million and $50 million, which represents a year-over-year growth of approximately 35% to 50%. The company believes its contracted revenue of $22.9 million for the remaining three quarters of 2026 provides useful visibility into the full year revenue. This outlook is based on continued strong demand for its AI-enabled underwriting marketplace and the successful deployment of new features. ### Related Stocks - [HIT.US](https://longbridge.com/en/quote/HIT.US.md) ## Related News & Research - [Health In Tech Showcases AI Platform in Investor Presentation](https://longbridge.com/en/news/286330879.md) - [Evercore ISI's Emanuel: July 4 could be 'breakpoint date' when oil prices spark an economic downturn](https://longbridge.com/en/news/286839181.md) - [Will Nvidia Hit the $6 Trillion Mark on Thursday?](https://longbridge.com/en/news/287019207.md) - [A key Treasury yield just hit its highest level since before the Great Financial Crisis](https://longbridge.com/en/news/286939313.md) - [When the AI Backlash Will Hit Your Portfolio](https://longbridge.com/en/news/286966932.md)